Allergan (NYSE: AGN)‘s stock had its “buy” rating restated by analysts at TheStreet in a research report issued to clients and investors on Wednesday.
The analysts wrote, “Allergan (AGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of A+ . The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”
Several other analysts have also recently commented on the stock. Analysts at SunTrust reiterated a “buy” rating on shares of Allergan in a research note to investors on Thursday, February 21st. They now have a $121.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Allergan in a research note to investors on Thursday, February 7th. They now have a $114.00 price target on the stock. Finally, analysts at Citigroup raised their price target on shares of Allergan from $106.00 to $124.00 in a research note to investors on Thursday, February 7th. They now have a “buy” rating on the stock.
Twenty research analysts have rated the stock with a buy rating, two have issued an overweight rating, and seven have given a hold rating to the company. Allergan currently has a consensus rating of “overweight” and a consensus target price of $114.73.
Shares of Allergan traded up 1.35% during mid-day trading on Wednesday, hitting $108.49. Allergan has a 52 week low of $81.28 and a 52 week high of $109.31. The stock’s 50-day moving average is currently $106.1. The company has a market cap of $32.525 billion and a P/E ratio of 29.90.
Allergan last posted its quarterly earnings results on Tuesday, February 5th. The company reported $1.15 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.20 by $0.05. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.51 million. During the same quarter in the prior year, the company posted $1.00 earnings per share. The company’s quarterly revenue was up 7.6% on a year-over-year basis. Allergan has set its Q1 guidance at $0.94-0.96 EPS and its FY13 guidance at $4.75-4.83 EPS. Analysts expect that Allergan will post $4.76 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, March 21st. Shareholders of record on Thursday, February 28th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.18%. The ex-dividend date is Tuesday, February 26th.
Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
